- Home
- VERU vs KYTX Comparison
VERU vs KYTX Comparison
Compare VERU & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- KYTX
- Stock Information
- Founded
- VERU 1971
- KYTX 2018
- Country
- VERU United States
- KYTX United States
- Employees
- VERU N/A
- KYTX N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- KYTX
- Sector
- VERU Health Care
- KYTX
- Exchange
- VERU Nasdaq
- KYTX NYSE
- Market Cap
- VERU 76.9M
- KYTX 85.8M
- IPO Year
- VERU 1990
- KYTX 2024
- Fundamental
- Price
- VERU $0.54
- KYTX $2.10
- Analyst Decision
- VERU Strong Buy
- KYTX Buy
- Analyst Count
- VERU 3
- KYTX 5
- Target Price
- VERU $4.33
- KYTX $18.80
- AVG Volume (30 Days)
- VERU 2.0M
- KYTX 289.0K
- Earning Date
- VERU 05-07-2025
- KYTX 05-13-2025
- Dividend Yield
- VERU N/A
- KYTX N/A
- EPS Growth
- VERU N/A
- KYTX N/A
- EPS
- VERU N/A
- KYTX N/A
- Revenue
- VERU $16,886,419.00
- KYTX N/A
- Revenue This Year
- VERU N/A
- KYTX N/A
- Revenue Next Year
- VERU N/A
- KYTX N/A
- P/E Ratio
- VERU N/A
- KYTX N/A
- Revenue Growth
- VERU 22.46
- KYTX N/A
- 52 Week Low
- VERU $0.45
- KYTX $1.78
- 52 Week High
- VERU $1.75
- KYTX $17.55
- Technical
- Relative Strength Index (RSI)
- VERU 49.37
- KYTX 47.94
- Support Level
- VERU $0.51
- KYTX $2.02
- Resistance Level
- VERU $0.56
- KYTX $2.23
- Average True Range (ATR)
- VERU 0.04
- KYTX 0.20
- MACD
- VERU 0.00
- KYTX 0.05
- Stochastic Oscillator
- VERU 38.00
- KYTX 65.31
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.